Advances in virus-directed therapeutics against epstein-barr virus-associated malignancies

Advances in Virology

Volumn 2012, Issue , 2012, Pages

  Ghosh, Sajal K ^a   Perrine, Susan P ^a   Faller, Douglas V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

EID: 84872477154     PISSN: 16878639     EISSN: 16878647     Source Type: Journal    
DOI: 10.1155/2012/509296     Document Type: Review

References (90)

1. Straus S. E., Cohen J. I., Tosato G., Meier J., Epstein-Barr virus infections: biology, pathogenesis, and management. Annals of Internal Medicine 1993 118 1 45 58 2-s2.0-0027506845
2. Henle G., Henle W., Diehl V., Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proceedings of the National Academy of Sciences of the United States of America 1968 59 1 94 101 2-s2.0-0014223978
3. Purtilo D. T., X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology. Springer Seminars in Immunopathology 1991 13 2 181 197 2-s2.0-0026323343
4. Morra M., Howie D., Grande M. S., Sayos J., Wang N., Wu C., Engel P., Terhorst C., X-linked lymphoproliferative disease: a progressive immunodeficiency. Annual Review of Immunology 2001 19 657 682 2-s2.0-0035063939 10.1146/annurev.immunol.19.1.657
5. Liebowitz D., Nasopharyngeal carcinoma: the Epstein-Barr virus association. Seminars in Oncology 1994 21 3 376 381 2-s2.0-0028355939
6. Epstein M. A., Achong B. G., Barr Y. M., Virus particles in cultured lymphoblasts from Burkitt's lymphoma. The Lancet 1964 283 7335 702 703 2-s2.0-49749222804
7. Hopwood P., Crawford D. H., The role of EBV in post-transplant malignancies: a review. Journal of Clinical Pathology 2000 53 4 248 254 2-s2.0-0034070035 10.1136/jcp.53.4.248
8. Chao N. J., Berry G. J., Advani R., Horning S. J., Weiss L. M., Blume K. G., Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Transplantation 1993 55 6 1425 1428 2-s2.0-0027217752
9. Ho M., Jaffe R., Miller G., Breinig M. K., Dummer J. S., Makowka L., Atchison R. W., Karrer F., Nalesnik M. A., Starzl T. E., The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988 45 4 719 727 2-s2.0-0023890609
10. Penn I., Malignant lymphomas in organ transplant recipients. Transplantation Proceedings 1981 13 1 736 738 2-s2.0-0019422160
11. Weiss L. M., Movahed L. A., Warnke R. A., Sklar J., Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. The New England Journal of Medicine 1989 320 8 502 506 2-s2.0-0024564527
12. Ott G., Kirchner T. H., Muller-Hermelink H. K., Monoclonal Epstein-Barr virus genomes but lack of EBV-related protein expression in different types of gastric carcinoma. Histopathology 1994 25 4 323 329 2-s2.0-0028006875
13. Yuen S. T., Chung L. P., Leung S. Y., Luk I. S. C., Chan S. Y., Ho J., In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas. American Journal of Surgical Pathology 1994 18 11 1158 1163 2-s2.0-0028099493
14. Bonnet M., Guinebretiere J. M., Kremmer E., Grunewald V., Benhamou E., Contesso G., Joab I., Detection of Epstein-Barr virus in invasive breast cancers. Journal of the National Cancer Institute 1999 91 16 1376 1381 2-s2.0-0033581152
15. Arbach H., Viglasky V., Lefeu F., Guinebretière J. M., Ramirez V., Bride N., Boualaga N., Bauchet T., Peyrat J. P., Mathieu M. C., Mourah S., Podgorniak M. P., Seignerin J. M., Takada K., Joab I., Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (taxol). Journal of Virology 2006 80 2 845 853 2-s2.0-30344458825 10.1128/JVI.80.2.845-853.2006
16. Glaser S. L., Hsu J. L., Gulley M. L., Epstein-Barr Virus and breast cancer: state of the evidence for viral carcinogenesis. Cancer Epidemiology Biomarkers and Prevention 2004 13 5 688 697 2-s2.0-2942519289
17. Diepstra A., Van Imhoff G. W., Schaapveld M., Karim-Kos H., Van Den Berg A., Vellenga E., Poppema S., Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. Journal of Clinical Oncology 2009 27 23 3815 3821 2-s2.0-68949088571 10.1200/JCO.2008.20.5138
18. Tsimberidou A. M., Keating M. J., Bueso-Ramos C. E., Kurzrock R., Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leukemia and Lymphoma 2006 47 5 827 836 2-s2.0-33744928408 10.1080/ 10428190500398856
19. Park S., Lee J., Young H. K., Han A., Hyun J. J., Sang C. L., In G. H., Yeon H. P., Jin S. A., Chul W. J., Kim K., Yong C. A., Won K. K., Park K., Won S. K., The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007 110 3 972 978 2-s2.0-34547947640 10.1182/blood-2007-01-067769
20. Paydas S., Ergin M., Erdogan S., Seydaoglu G., Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leukemia Research 2008 32 9 1424 1430 2-s2.0-43049153419 10.1016/j.leukres.2008.01.008
21. Sasikala P. S., Nirmala K., Sundersingh S., Mahji U., Rajkumar T., Frequency and distribution of Epstein-Barr virus infection and its association with P53 expression in a series of primary nodal non-Hodgkin lymphoma patients from South India. International Journal of Laboratory Hematology 2010 32 1 56 64 2-s2.0-77449096723 10.1111/j.1751-553X.2008.01125.x
22. Carbone A., Cesarman E., Spina M., Gloghini A., Schulz T. F., HIV-associated lymphomas and gamma-herpesviruses. Blood 2009 113 6 1213 1224 2-s2.0-60849090778 10.1182/blood-2008-09-180315
23. Raab-Traub N., Flynn K., The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986 47 6 883 889 2-s2.0-0022895276
24. Brown N. A., Liu C., Garcia C. R., Clonal origins of lymphoproliferative disease induced by Epstein-Barr virus. Journal of Virology 1986 58 3 975 978 2-s2.0-0022517075
25. Hammerschmidt W., Sugden B., Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 1988 55 3 427 433 2-s2.0-0023698910
26. Neri A., Barriga F., Inghirami G., Knowles D. M., Neequaye J., Magrath I. T., Dalla-Favera R., Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 1991 77 5 1092 1095 2-s2.0-0026100617
27. Henle G., Henle W., Horwitz C. A., Antibodies to Epstein Barr virus associated nuclear antigen in infectious mononucleosis. Journal of Infectious Diseases 1974 130 3 231 239 2-s2.0-0016139691
28. Henle G., Henle W., Clifford P., Diehl V., Kafuko G. W., Kirya B. G., Klein G., Morrow R. H., Munube G. M., Pike P., Tukei P. M., Ziegler J. L., Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. Journal of the National Cancer Institute 1969 43 5 1147 1157 2-s2.0-0014596168
29. Henle W., Henle G., Epstein M., Achong B., Seroepidemiology of the virus. The Epstein-Barr Virus 1979 Berlin Springer 61 78
30. Rickinson A. B., Moss D. J., Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annual Review of Immunology 1997 15 405 431 2-s2.0-0030889206 10.1146/annurev.immunol.15.1.405
31. Tan L. C., Gudgeon N., Annels N. E., Hansasuta P., O'Callaghan C. A., Rowland-Jones S., McMichael A. J., Rickinson A. B., Callan M. F. C., A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. Journal of Immunology 1999 162 3 1827 1835 2-s2.0-0033082487
32. Sugden B., Mark W., Clonal transformation of adult human leukocytes by Epstein-Barr virus. Journal of Virology 1977 23 3 503 508 2-s2.0-0017659644
33. Cohen J. I., Epstein-Barr virus and the immune system: hide and seek. Journal of the American Medical Association 1997 278 6 510 513 2-s2.0-0030761670
34. Jackman W. T., Mann K. A., Hoffmann H. J., Spaete R. R., Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 1999 17 7-8 660 668 2-s2.0-0033605232 10.1016/S0264-410X(98) 00248-5
35. Thomson S. A., Burrows S. R., Misko I. S., Moss D. J., Coupar B. E. H., Khanna R., Targeting a polyepitope protein incorporating multiple class II- restricted vital epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. Journal of Virology 1998 72 3 2246 2252 2-s2.0-0031911648
36. Rickinson A. B., Kieff E., Fields B. N., Knipe D. M., Howley P. M., Epstein-Barr virus. Fields Virology 1996 3rd Philadelphia, Pa, USA Lippincott-Raven
37. Sokal E. M., Hoppenbrouwers K., Vandermeulen C., Moutschen M., Léonard P., Moreels A., Haumont M., Bollen A., Smets F., Denis M., Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. Journal of Infectious Diseases 2007 196 12 1749 1753 2-s2.0-39149121505 10.1086/523813
38. Moutschen M., Léonard P., Sokal E. M., Smets F., Haumont M., Mazzu P., Bollen A., Denamur F., Peeters P., Dubin G., Denis M., Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 2007 25 24 4697 4705 2-s2.0-34248669298 10.1016/j.vaccine.2007.04.008
39. Papadopoulos E. B., Ladanyi M., Emanuel D., Mackinnon S., Boulad F., Carabasi M. H., Castro-Malaspina H., Childs B. H., Gillio A. P., Small T. N., Young J. W., Kernan N. A., O'Reilly R. J., Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. The New England Journal of Medicine 1994 330 17 1185 1191 2-s2.0-0028288519 10.1056/NEJM199404283301703
40. Rooney C. M., Smith C. A., Ng C. Y. C., Loftin S. K., Sixbey J. W., Gan Y., Srivastava D. K., Bowman L. C., Krance R. A., Brenner M. K., Heslop H. E., Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998 92 5 1549 1555 2-s2.0-0032170108
41. Khanna R., Bell S., Sherritt M., Galbraith A., Burrows S. R., Rafter L., Clarke B., Slaughter R., Falk M. C., Douglass J., Williams T., Elliott S. L., Moss D. J., Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proceedings of the National Academy of Sciences of the United States of America 1999 96 18 10391 10396 2-s2.0-13044295992 10.1073/pnas.96.18.10391
42. Chua D., Huang J., Zheng B., Lau S. Y., Luk W., Kwong D. L. W., Sham J. S. T., Moss D., Yuen K. Y., Im S. W. K., Ng M. H., Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. International Journal of Cancer 2001 94 1 73 80 2-s2.0-17944381522 10.1002/ijc.1430
43. Bollard C. M., Aguilar L., Straathof K. C., Gahn B., Huls M. H., Rousseau A., Sixbey J., Gresik M. V., Carrum G., Hudson M., Dilloo D., Gee A., Brenner M. K., Rooney C. M., Heslop H. E., Cytotoxic T lymphocyte therapy for epstein-barr virus+ Hodgkin's disease. Journal of Experimental Medicine 2004 200 12 1623 1633 2-s2.0-19944426160 10.1084/jem.20040890
44. Straathof K. C. M., Bollard C. M., Popat U., Huls M. H., Lopez T., Morriss M. C., Gresik M. V., Gee A. P., Russell H. V., Brenner M. K., Rooney C. M., Heslop H. E., Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005 105 5 1898 1904 2-s2.0-20144365643 10.1182/blood-2004-07-2975
45. Gustafsson A., Levitsky V., Zou J. Z., Frisan T., Dalianis T., Ljungman P., Ringden O., Winiarski J., Ernberg I., Masucci M. G., Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000 95 3 807 814 2-s2.0-12944328008
46. Heslop H. E., hheslop@bcm.edu Slobod K. S., Pule M. A., Hale G. A., Rousseau A., Smith C. A., Bollard C. M., Liu H., Wu M. -F., Rochester R. J., Amrolia P. J., Hurwitz J. L., Brenner M. K., Rooney C. M., Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010 115 5 925 935 10.1182/blood-2009-08-239186
47. Murray R. J., Kurilla M. G., Brooks J. M., Thomas W. A., Rowe M., Kieff E., Rickinson A. B., Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV- positive malignancies. Journal of Experimental Medicine 1992 176 1 157 168 2-s2.0-0026734842 10.1084/jem.176.1.157
48. Louis C. U., Straath K., Bollard C. M., Gerken C., Huls M. H., Gresik M. V., Wu M. F., Weiss H. L., Gee A. P., Brenner M. K., Rooney C. M., Heslop H. E., Gottschalk S., Enhancing the in vivo expansion of adoptively transferred EBV- Specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009 113 11 2442 2450 2-s2.0-63849262293 10.1182/blood-2008-05-157222
49. Merlo A., Turrini R., Dolcetti R., Zanovello P., Rosato A., antonio.rosato@unipd.it Immunotherapy for EBV-associated malignancies. International Journal of Hematology 2011 93 3 281 293 10.1007/s12185-011-0782-2
50. Chodosh J., Holder V. P., Gan Y. J., Belgaumi A., Sample J., Sixbey J. W., Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. Journal of Infectious Diseases 1998 177 5 1194 1201 2-s2.0-0031900086
51. Slobod K. S., Taylor G. H., Sandlund J. T., Furth P., Helton K. J., Sixbey J. W., Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. The Lancet 2000 356 9240 1493 1494 2-s2.0-0034727395
52. Kenney J. L., Guinness M. E., Curiel T., Lacy J., Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and Bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998 92 5 1721 1727 2-s2.0-0032170456
53. Hirai H., Satoh E., Osawa M., Inaba T., Shimazaki C., Kinoshita S., Nakagawa M., Mazda O., Imanishi J., Use of EBV-based vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. Biochemical and Biophysical Research Communications 1997 241 1 112 118 2-s2.0-17144462753 10.1006/bbrc.1997.7776
54. Kenney S., Ge J. I. Q., Westphal E. M., Olsen J., Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Human Gene Therapy 1998 9 8 1131 1141 2-s2.0-0032550754
55. Moolten F. L., Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Research 1986 46 10 5276 5281 2-s2.0-0022485359
56. Gutiérrez M. I., Judde J. G., Magrath I. T., Bhatia K. G., Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Research 1996 56 5 969 972 2-s2.0-0030067422
57. Westphal E. M., Mauser A., Swenson J., Davis M. G., Talarico C. L., Kenney S. C., Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Research 1999 59 7 1485 1491 2-s2.0-0033118418
58. Feng W. H., Westphal E., Mauser A., Raab-Traub N., Gulley M. L., Busson P., Kenney S. C., Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. Journal of Virology 2002 76 21 10951 10959 2-s2.0-0036838606 10.1128/JVI.76.21.10951-10959. 2002
59. Israel B. F., Kenney S. C., Virally targeted therapies for EBV-associated malignancies. Oncogene 2003 22 33 5122 5130 2-s2.0-0041465971 10.1038/sj.onc.1206548
60. Ben-Sasson S. A., Klein G., Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines. International Journal of Cancer 1981 28 2 131 135 2-s2.0-0019410144
61. Hudewentz J., Bornkamm G. W., Zur Hausen H., Effect of the diterpene ester TPA on Epstein-Barr virus antigen- and DNA synthesis in producer and nonproducer cell lines. Virology 1980 100 1 175 178 2-s2.0-0018835322
62. Luka J., Kallin B., Klein G., Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 1979 94 1 228 231 2-s2.0-0018384722
63. Anisimova E., Prachova K., Roubal J., Vonka V., Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation. Archives of Virology 1984 81 3-4 223 237 2-s2.0-0021280711
64. Saemundsen A. K., Kallin B., Klein G., Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus. Virology 1980 107 2 557 561 2-s2.0-0019176585
65. Farrell P. J., Rowe D. T., Rooney C. M., Kouzarides T., Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. The EMBO Journal 1989 8 1 127 132 2-s2.0-0024469056
66. Tao Q., Robertson K. D., Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clinical Immunology 2003 109 1 53 63 2-s2.0-0142247170 10.1016/S1521-6616(03)00198-0
67. Park J. H., Faller D. V., Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation. Virology 2002 303 2 345 363 2-s2.0-0036943615 10.1006/viro.2002.1638
68. Sealy L., Chalkley R., The effect of sodium butyrate on histone modification. Cell 1978 14 1 115 121 2-s2.0-0017864644
69. Sarkar S., Abujamra A. L., Loew J. E., Forman L. W., Perrine S. P., Faller D. V., dfaller@bu.edu Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Research 2011 31 9 2723 2732
70. Mentzer S. J., Fingeroth J., Reilly J. J., Perrine S. P., Faller D. V., Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells, Molecules and Diseases 1998 24 2 114 123 2-s2.0-0032104738 10.1006/bcmd.1998.0178
71. Westphal E. M., Blackstock W., Feng W., Israel B., Kenney S. C., Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Research 2000 60 20 5781 5788 2-s2.0-0034667460
72. Faller D. V., Mentzer S. J., Perrine S. P., Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Current Opinion in Oncology 2001 13 5 360 367 2-s2.0-0034858563 10.1097/00001622- 200109000-00008
73. Faller D. V., Hermine O., Small T., Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr virus (EBV)-associated lymphoma. Blood (ASH Annual Meeting Abstracts) 2000 96, abstract 577
74. Perrine S. P., Hermine O., Small T., Suarez F., O'Reilly R., Boulad F., Fingeroth J., Askin M., Levy A., Mentzer S. J., Di Nicola M., Gianni A. M., Klein C., Horwitz S., Faller D. V., A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007 109 6 2571 2578 2-s2.0-33947275876 10.1182/blood-2006- 01-024703
75. Moore S. M., Cannon J. S., Tanhehco Y. C., Hamzeh F. M., Ambinder R. F., Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrobial Agents and Chemotherapy 2001 45 7 2082 2091 2-s2.0-0034954624 10.1128/AAC.45.7.2082-2091.2001
76. Mentzer S. J., Perrine S. P., Faller D. V., Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transplant Infectious Disease 2001 3 3 177 185 2-s2.0-0034870826 10.1034/j.1399-3062.2001.003003177.x
77. Feng W. H., Kenney S. C., Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Research 2006 66 17 8762 8769 2-s2.0-33749031579 10.1158/0008-5472.CAN- 06-1006
78. Ghosh S. K., Forman L. W., Akinsheye I., Perrine S. P., Faller D. V., Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. Blood Cells, Molecules, and Diseases 2007 38 1 57 65 2-s2.0-33845599154 10.1016/j.bcmd.2006.10.008
79. Roychowdhury S., Peng R., Baiocchi R. A., Bhatt D., Vourganti S., Grecula J., Gupta N., Eisenbeis C. F., Nuovo G. J., Yang W., Schmalbrock P., Ferketich A., Moeschberger M., Porcu P., Barth R. F., Caligiuri M. A., Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Research 2003 63 5 965 971 2-s2.0-0037374285
80. Daibata M., Bandobashi K., Kuroda M., Imai S., Miyoshi I., Taguchi H., Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo. Journal of Virology 2005 79 9 5875 5879 2-s2.0-17444411923 10.1128/JVI.79.9.5875-5879.2005
81. Fu D. X., Tanhehco Y., Chen J., Foss C. A., Fox J. J., Chong J. M., Hobbs R. F., Fukayama M., Sgouros G., Kowalski J., Pomper M. G., Ambinder R. F., Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nature Medicine 2008 14 10 1118 1122 2-s2.0-53549087773 10.1038/nm.1864
82. Feng W. H., Israel B., Raab-Traub N., Busson P., Kenney S. C., Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Research 2002 62 6 1920 1926 2-s2.0-0037086080
83. Feng W. H., Hong G., Delecluse H. J., Kenney S. C., Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. Journal of Virology 2004 78 4 1893 1902 2-s2.0-0842326026 10.1128/JVI.78.4.1893-1902.2004
84. Fu D. X., Tanhehco Y. C., Chen J., Foss C. A., Fox J. J., Lemas V., Chong J. M., Ambinder R. F., Pomper M. G., Virus-associated tumor imaging by induction of viral gene expression. Clinical Cancer Research 2007 13 5 1453 1458 2-s2.0-33947419410 10.1158/1078-0432.CCR-06-2295
85. Faller D. V., Ghosh S., Feldman T., Short-term exposure to arginine butyrate, in combination with ganciclovir, is as effective as continuous exposure for virus-targeted therapy of EBV-positive lymphomas. Blood (ASH Annual Meeting Abstracts) 2009 114, abstract 4754
86. Xu W. S., Parmigiani R. B., Marks P. A., Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007 26 37 5541 5552 2-s2.0-34547864236 10.1038/sj.onc.1210620
87. Mercurio C., Minucci S., Pelicci P. G., Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacological Research 2010 62 1 18 34 2-s2.0-77952853306 10.1016/j.phrs.2010.02.010
88. Ye J., Gradoville L., Daigle D., Miller G., De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists. Journal of Virology 2007 81 17 9279 9291 2-s2.0-34548147218 10.1128/JVI.00982-07
89. Faller D. V., Ghosh S., Perrine S. P., Williams R. M., Berenson R. J., Histone deacetylase inhibitors: potent inducers of tumor latent EBV thymidine kinase induction. Blood (ASH Annual Meeting Abstracts) 2011 118, abstract 1831
90. Ghosh S. K., Perrine S. P., Williams R. M., Faller D. V., Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside anti-viral agents. Blood 2012 119 4 1008 1017 10.1182/blood-2011-06-362434